Related Experiment Video
Updated: Apr 8, 2026
11:21
Robotic Ablation of Atrial Fibrillation
Published on: May 29, 2015
20.4K
Lerodalcibep: First Approval
Amy Zhuang-Yan1, Hannah A Blair2
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
Drugs
|April 7, 2026
Summary
Lerodalcibep, a new subcutaneous PCSK9 inhibitor, is approved in the USA for treating hypercholesterolemia. This therapy helps reduce low-density lipoprotein cholesterol (LDL-C) in adults, offering a new option for managing high cholesterol.
Area of Science:
- Cardiovascular medicine
- Pharmacology
- Drug development
Background:
- Hypercholesterolemia poses significant cardiovascular risks.
- Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors offer a novel therapeutic approach.
- Third-generation PCSK9 inhibitors aim for improved efficacy and administration profiles.
Purpose of the Study:
- To summarize the development milestones of lerodalcibep.
- To highlight the regulatory approval of lerodalcibep for hypercholesterolemia treatment.
- To detail the drug's mechanism and administration.
Main Methods:
- Review of preclinical and clinical development data for lerodalcibep.
- Analysis of regulatory submission and approval processes.
- Pharmacological characterization of lerodalcibep as a PCSK9 inhibitor.
Main Results:
- Lerodalcibep, a third-generation PCSK9 inhibitor, has completed development.
- Received first regulatory approval in the USA on December 12, 2025.
- Approved as an adjunct to diet and exercise for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.
Conclusions:
- Lerodalcibep represents a significant advancement in hypercholesterolemia management.
- The subcutaneous, once-monthly injection offers a convenient administration route.
- This approval provides a new therapeutic option for reducing low-density lipoprotein cholesterol (LDL-C).
More Related Videos
Related Concept Videos
01:26FDA Approved Drugs: Changes to Approved Drugs
330
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
330
01:02Prescription, Nonprescription and Orphan Drugs
1.4K
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
1.4K
01:26Drug Administration and Therapy Phases: Overview
1.7K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.7K
01:21Drugs for Treatment of Constipation-Predominant IBS
1.3K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.3K
01:29Clinically Relevant Drug Product Specifications: Methods of Establishment
285
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
285
01:25Drug Regulation
3.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.3K